BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
1.591
+0.021 (1.34%)
Aug 17, 2026, 2:10 PM EDT - Market open
BioNexus Gene Lab Revenue
BioNexus Gene Lab had revenue of $76.16K in the quarter ending June 30, 2026, a decrease of -96.63%. This brings the company's revenue in the last twelve months to $3.13M, down -67.27% year-over-year. In the year 2025, BioNexus Gene Lab had annual revenue of $7.42M, down -21.93%.
Revenue (ttm)
$3.13M
Revenue Growth
-67.27%
P/S Ratio
1.21
Revenue / Employee
$164,557
Employees
19
Market Cap
3.85M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.42M | -2.09M | -21.93% |
| Dec 31, 2024 | 9.51M | -260.16K | -2.66% |
| Dec 31, 2023 | 9.77M | -1.16M | -10.60% |
| Dec 31, 2022 | 10.93M | -2.43M | -18.21% |
| Dec 31, 2021 | 13.36M | 1.97M | 17.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hudson Technologies | 256.92M |
| Core Molding Technologies | 254.42M |
| Aemetis | 230.17M |
| Northern Technologies International | 91.84M |
| Flexible Solutions International | 35.58M |
| CN Energy Group. | 35.57M |
| Bon Natural Life | 18.67M |
| J-Star Holding | 9.93M |
BGLC News
- 20 days ago - BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit - GlobeNewsWire
- 2 months ago - BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development - GlobeNewsWire
- 5 months ago - Bionexus Gene Lab appoints Muthu Meyyappan as CCO, Fidelion - TheFly
- 5 months ago - BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform - GlobeNewsWire
- 6 months ago - Bionexus Gene Lab appoints Matthew Barsing as Chairman - TheFly
- 6 months ago - BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman - GlobeNewsWire
- 7 months ago - Bionexus Gene Lab announces formal commencement of 2026 Deployment Phase - TheFly
- 7 months ago - BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market - GlobeNewsWire